Evaluation of $^{18}$F-CPFPX, a Novel Adenosine A$_1$ Receptor Ligand: In Vitro Autoradiography and High-Resolution Small Animal PET

Andreas Bauer, MD$^1$; Marcus H. Holschbach, PhD$^2$; Markus Cremer$^1$; Simone Weber, PhD$^1$; Christian Boy, MD$^1$; N. Jon Shah, PhD$^3$; Ray A. Olsson, MD$^4$; Horst Halling, PhD$^3$; Heinz H. Coenen, PhD$^2$; and Karl Zilles, MD$^1,5$

$^1$Institute of Medicine, Research Center Jülich, Jülich, Germany; $^2$Institute of Nuclear Chemistry, Research Center Jülich, Jülich, Germany; $^3$Central Electronics Laboratory, Research Center Jülich, Jülich, Germany; $^4$Department of Internal Medicine, University of South Florida, Tampa, Florida; and $^5$C. and O. Vogt Institute of Brain Research, University of Düsseldorf, Düsseldorf, Germany

Adenosine modulates brain activity through $G$ protein–coupled receptors, primarily adenosine A$_1$ receptors (A$_1$ARs). A$_1$ARs are heterogeneously distributed throughout the brain and participate in many physiologic processes—for example, the induction of sleep and feedback inhibition of excitatory neurotransmission. There is also evidence that A$_1$ARs are involved in brain pathologies, including cerebral ischemia, epilepsy, and neurodegeneration. Therefore, measuring A$_1$ARs in the living brain has been a long-standing goal. This report describes the preclinical evaluation of $^{18}$F-8-cyclopentyl-1,3-dipropylxanthine ($^{18}$F-CPFPX), a novel A$_1$AR PET ligand. Methods: CPFPX, a xanthine-based A$_1$AR antagonist, was labeled with either $^{18}$F or $^3$H, maintaining identical chemical structures, and evaluated in rats as a putative radioligand for in vivo or in vitro imaging of brain A$_1$ARs by quantitative receptor autoradiography and the combination of high-resolution small animal PET and MRI. Results: $^{18}$F-CPFPX bind with nanomolar affinity (K$_D$, 4.4 nmol/L) to A$_1$ARs and showed a distribution typical of cerebral A$_1$ARs. In extensive in vitro competition studies, $^3$H-CPFPX proved to be a highly selective and specific A$_1$AR radioligand. Neither the nonxanthine-type adenosine A$_2A$ receptor antagonist ZM 241385 nor multiple cholinergic, serotoninergic, and glutamatergic receptor compounds competed for $^3$H-CPFPX. Low binding potentials were found in the midbrain. Retention of $^{18}$F-CPFPX was highest in the allocortical regions, as well as in the basal ganglia, thalamus, and cerebellum (4–6). The A$_1$AR seems to have an inhibitory net effect on neuronal tissue, although this is still a matter of debate (7). There is evidence that adenosine contributes to the induction and maintenance of sleep and the regulation of arousal (8–10), functions as a retrograde synaptic messenger (11), and plays a role in the autoregulation of cerebral blood flow (12). A$_1$ARs are involved in multiple pathologic conditions of the brain—for example, epilepsy (13) and neurodegenerative diseases, including Alzheimer’s dementia (14–16).

Adenosine, an endogenous purine, exerts its physiologic actions via $G$ protein–coupled receptors, 4 of which (A$_1$, A$_2A$, A$_2B$, A$_3$) have been pharmacologically characterized and cloned in several species, including rats and humans (1–3). Each subtype of adenosine receptor is heterogeneously distributed throughout the body, particularly in excitable tissues such as heart and brain. The A$_1$AR subtype is the most abundant adenosine receptor in the brain and is distributed in a heterogeneous pattern in neocortical and allocortical regions, as well as in the basal ganglia, thalamus, and cerebellum (4–6). A$_1$ARs in particular high in gray matter regions. Retention of $^{18}$F-CPFPX was highest in the cerebellum, thalamus, and neocortex with evidence of saturable binding. Low binding potentials were found in the midbrain. In vivo displacement PET experiments with the A$_1$AR antagonist 8-cyclopentyl-1,3-dipropylxanthine showed a 72% ± 8% displacement of $^{18}$F-CPFPX. Conclusion: $^{18}$F-CPFPX is a highly selective and specific ligand for A$_1$ARs and a suitable radioligand for noninvasive PET imaging of A$_1$ARs in the living brain. These studies also support the application of high-resolution animal PET as an effective in vivo imaging tool in the evaluation process of new radioligands.

Key Words: brain; adenosine A$_1$ receptor; high-resolution animal PET; quantitative receptor autoradiography

serious limitations to the routine application of $^{11}$C-KF15372 occurred. Due to the multistep and time-consuming radiosynthesis in combination with the short physical half-life of $^{11}$C (20.4 min), the radiochemical yield of $^{11}$C-KF15372 was relatively low (~5%) and specific activity ($A_s$) was in the range of 10–56 GBq/$\mu$mol (0.3–1.5 Ci/$\mu$mol). Brain uptake in mice after intravenous injection was 1.9% of injected dose per gram after 5 min and fell thereafter (17). The content of radioligand was high in hippocampus, cerebral and cerebellar cortex, and caudate-putamen. The administration of unlabeled ligand reduced the content of the radioligand to about 45% of the control level (18).

Most important, however, the low rates in both radiochemical yield and $A_s$ impose severe restrictions to the routine application of $^{11}$C-KF15372. The evaluation of $^{11}$C-MPDX was much higher and washout was faster than that of $^{11}$C-KF15372, however, was relatively fast in comparison with the other compounds (19). $^{11}$C-KF15372 and $^{11}$C-MPDX have since been tested in monkey studies. Both tracers showed the same brain distribution. Brain uptake of $^{11}$C-MPDX (inhibition constant [$K_i$], 4.2 mmol/L) was much higher and washout was faster than that of $^{11}$C-KF15372 ($K_i$, 3.0 mmol/L). Cerebral binding was blocked by carrier loading or displacement by an $\alpha_1$AR antagonist. The regional cerebral binding pattern as evaluated with kinetic analysis was consistent with data reported from previous in vitro studies (20,27). Up to now, there is no report that any of these $^{11}$C-labeled radioligands have reached the stage of human studies.

This report describes the preclinical evaluation of the novel xanthine-based $\alpha_1$AR antagonist 8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX). The ligand is an analog of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), which, due to its high selectivity and affinity for $\alpha_1$ARs, is the prototypical $\alpha_1$AR antagonist (22–24). The synthesis and pharmacologic in vitro characterization of CPFPX as well as the method for the radiosynthesis of noncarrier-added $^{18}$F-CPFPX have recently been published (25). $^{18}$F-CPFPX is routinely produced and reliably obtained ready for injection in about 55-min overall synthesis time with a radiochemical yield of 45% ± 7% (7.5 ± 0.5 GBq [200 ± 20 mCi]; $n = 22$), a radiochemical purity of >98%, and an $A_s$ of >270 GBq/$\mu$mol (>7.5 Ci/$\mu$mol) at the end of synthesis. $^{18}$F-CPFPX shows excellent in vitro stability at room temperature in aqueous solution without any indication of disintegration products up to 6 h after preparation. The octanol–water partition coefficient (log P value) is 2.1 ± 0.15, indicating that $^{18}$F-CPFPX is sufficiently lipophilic to cross the blood–brain barrier.

In rat striatal membranes, $^{18}$F-CPFPX showed a nanomolar affinity for $\alpha_1$ARs and a 1,200-fold selectivity for $\alpha_1$ARs over $\alpha_2$ARs. In mice, brain uptake was high, and specific binding accounted for 70%–80% of the radioactivity. The radioligand was stable after penetrating the blood–brain barrier but underwent degradation into at least 2 polar metabolites in blood (25).

In this article we discuss in vitro autoradiographic competition studies, in vivo high-resolution small animal PET, and ex vivo dissection techniques to further evaluate $^{18}$F-CPFPX for its future use as a PET ligand in nonhuman primates and in humans.

**MATERIALS AND METHODS**

**Radiopharmaceuticals and Chemicals**

CPFPX was synthesized in house as previously described (25). Noncarrier-added radiolabeling of CPFPX with $^{18}$F has also been published (26). The target compound $^{18}$F-CPFPX was obtained with a radiochemical yield of 45% ± 7% and a radiochemical purity of >98%. The $A_s$ of the product was in the range of >270 GBq/$\mu$mol (>7.5 Ci/$\mu$mol). $^{18}$F-CPFPX was formulated in 0.9% NaCl/7% ethanol for the purpose of intravenous injection.

$^3$H-CPFPX ($A_s$, 2.179 GBq/mmol [58.9 Ci/mmol]) was synthesized as recently described (27). The radiochemical purity was >98% as determined by high-pressure liquid chromatography. The $^3$H- and $^3$H-labeled probes of CPFPX had identical chemical and pharmacologic properties.

$^3$H-DPCPX ($A_s$, 4.129 GBq/mmol [111.6 Ci/mmol]) and $^3$H-4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]-ethyl)phenol ($^3$H-ZM 241385; $A_s$, 629 GBq/mmol [17 Ci/mmol]) were purchased from New England Nuclear.

Adenosine deaminase, (R)–N(2-phenylisopropyl)adenosine (R–PIA), caffeine, dopamine, phentolamine, nicotine, carbachol, l-glutamate, and $\gamma$-aminobutyric acid were purchased from Sigma-Aldrich Co. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) and ZM 241385 were purchased from Tocris Cookson Ltd. All other chemicals were of reagent grade and obtained commercially.

**Animals**

Adult male Wistar rats (bred in house; 230–250 g body weight) were used. All animals were kept under a natural light/dark cycle and had unlimited access to water and food. The local government approved all procedures according to the German Law on the Protection of Animals. Animal experiments were also approved by the Animal Research Committee of the Scientific and Technical Advisory Board of the Research Center Jülich.

**Autoradiographic In Vitro Studies**

Animals were decapitated between 6 and 9 AM. Whole brains were rapidly removed, blotted free of excess blood, and immediately frozen in 2-methylbutane (−50°C). Subsequently, the brains were cut in a cryostat microtome (CM 3050; Leica; section thickness, 20 μm) at −20°C. Sections were thaw-mounted onto silica-coated object slides, stored in a desiccator containing silica gel, dried overnight at 4°C, and stored adjacent at −80°C in plastic bags until use.

Incubation conditions for $^3$H-CPFPX and $^3$H-DPCPX were identical and similar to those previously described by other groups (4,28). All incubations were performed at 22°C in a TRIS-HCl buffer (170 mMol/L, pH 7.4) containing 2 international units (IU)/L adenosine deaminase and MgCl2 (1 mMol/L). Sections were preincubated in buffer for 20 min and subsequently incubated with 4.4 mMol/L $^3$H-CPFPX or 1.0 mMol/L $^3$H-DPCPX for 120 min with or without displacer, respectively. They were washed twice in...
ice-cold buffer (2 × 5 min), rapidly rinsed in ice-cold distilled water, and finally placed under a stream of dry air to facilitate rapid drying. Nonspecific binding was defined as the residual activity in the presence of 100 μmol/L (R−)-PIA. Specific binding was calculated as the difference between total and nonspecific binding.

3H-ZM 241385 was incubated in a TRIS-HCl buffer (170 mmol/L, pH 7.4). Sections were preincubated for 30 min at 37°C in buffer containing ethylenediaminetetraacetic acid (1 mmol/L) and 2 IU/L adenosine deaminase. Sections were washed twice for 10 min at 22°C in incubation buffer containing 10 mmol/L MgCl₂ and subsequently incubated with 0.4 mmol/L 3H-ZM 241385 for 120 min at 22°C in buffer containing 2 IU/L adenosine deaminase and MgCl₂ (10 mmol/L). Nonspecific binding was defined as the activity remaining in the presence of 2-chloroadenosine (20 μmol/L). Sections were finally washed twice for 5 min in ice-cold buffer, briefly dipped into distilled water, and subsequently dried under a stream of dry air.

A series of adjacent sections of all autoradiographs was stained by Nissl’s method and used for cytoarchitectural identification of brain nuclei and cortical regions.

Saturation Studies

Saturation experiments with 3H-CPFPX and 3H-DPCPX were performed to evaluate the respective dissociation constants, which define the ligand concentration of half-maximum receptor occupancy and allow an absolute quantification of receptor binding according to the equation: $R_T = R_S \times (K_d + F)/F$, where $R_T$ is total receptor concentration, $R_S$ is specific binding, $K_d$ is dissociation constant, and $F$ is free ligand concentration.

For saturation experiments, 4 quadruplicates of randomized coronal sections were chosen from different parts of the brain (caudate-putamen and dorsal hippocampus planes, respectively) and incubated in a series with rising concentrations of 3H-ligands and a parallel series with the addition of (R−)-PIA (100 μmol/L) to determine nonspecific binding.

High-Resolution Small Animal PET Studies

PET imaging of in vivo blockade and displacement experiments with 18F-CPFPX was performed on a prototype of a dedicated high-resolution small animal PET scanner (TierPET), which has previously been described (29,30). The TierPET scanner (Fig. 1) consists of 2 orthogonal pairs of detectors, which are mounted on linear feeds to adjust detector–detector distances individually (range, 16–58 cm; present experiment, 32 cm). Feeds are mounted on an aluminum wheel, which is rotated by 90° for the acquisition of complete projections (7.5° angular steps, step-and-shoot mode). Each detector module consists of a 20 × 20 array of 2 × 2 × 15 mm yttrium aluminum perovskite crystals, which are polished and optically isolated by reflective layers. The arrays are coupled to a Hamamatsu R2487 position-sensitive photomultiplier. The TierPET scanner runs in 3-dimensional mode and acquires data in list mode. List mode data are converted into 2-dimensional sinograms using a multiple-slice rebinning method (31). Two-dimensional sinograms are subsequently reconstructed using an iterative reconstruction based on the maximum-likelihood expectation maximization algorithm. Reconstructed image resolution is 2.1 mm (full width at half maximum), which is homogeneously maintained throughout the entire field of view. To reduce scatter-related perturbations, the neck and body of the animal were shielded with a hollow lead sleeve perfused with water heated to 37°C to maintain a constant body temperature. A precise anatomic identification of rat brain regions was achieved by coregistration with structural MR images (Siemens Magnetom VISION; 1.5 T, equipped with a dedicated transmit/receive radiofrequency coil and using a scanning sequence developed in house) and TierPET datasets. For this purpose, animals were placed in a transportable stereotactic head holder along with 3 fiducial markers, which served as spatial landmarks for PET and MRI. They were alternately filled with 18F for PET or cod liver oil for MRI. The head holder was screwed to an object tablet, which could be moved along the x-, y-, and z-axes by computer-controlled step motors, thus permitting a precise positioning of the animals within the field of view. Regions of interest (ROIs) were delineated on fusion images of MRI and TierPET datasets with dedicated software (Multi-Purpose-Imaging-Tool; ATV) (32).

Animals were sedated in an isoflurane atmosphere (2%–5%) and anesthetized with ketamine (100 mg/kg)/xylazine (10 mg/kg). After placing a jugular vein catheter, animals received a bolus injection of 0.3 mL 18F-CPFPX (37 MBq/mL [1 mCi] dissolved in 0.9% NaCl/7% ethanol). TierPET data were acquired for 60 min after injection in 10 frames of 6-min duration. Blood samples (~0.1 mL) were collected at 10, 20, 40, and 60 min after ligand administration to determine radioactivity and metabolites. Metabolite analysis was performed as previously described (25). In brief, venous plasma was obtained from heparinized whole blood samples (0.1 mL), diluted with methanol/dichloromethane (80:20, v/v, 0.2 mL), vortexed for 20 s at room temperature, and centrifuged (20,000g, 1 min). Aliquots (0.1 mL) of the supernatants were withdrawn, CPFPX (20 ng) was added, the mixtures were vortexed for 10 s, and samples (10–15 μL) were spotted onto thin-layer
chromatography plates (SIL G; Macherey-Nagel), which were developed with ethyl acetate/hexane (50:50, v/v) and analyzed using a high-performance image plate reader (InstantImager; Canberra Packard). In vivo distribution and displacement studies were performed in identical animals by intravenous application of 1 mg/kg DPCPX 12 min after the injection of ¹⁸F-CPFPX.

High-Resolution MRI

All animals underwent MRI scanning for anatomic comparison. Images were obtained using a whole-body MRI scanner (Siemens Magnetom VISION; 1.5 T) equipped with actively shielded gradient coils (maximum gradient strength, 25 mT/m; slew rate, 83 T/m/s). The animals were positioned, either individually or in pairs, inside a 22-cm-diameter transmit/receive radiofrequency coil. Anatomic images were obtained with a 3-dimensional gradient echo pulse sequence with a slab selection (slab thickness, 17 cm; effective slice thickness, 1 mm) along the sagittal orientation. Other acquisition parameters were field of view, 180 mm; matrix size, 256 × 256 with an in-planar resolution of 0.7 × 0.7 mm; number of excitations, 1. The total acquisition time was about 14 min. The final imaging resolution was 0.7 × 0.7 × 1.0 mm.

Autoradiographic Ex Vivo Studies

To confirm reliability of the in vivo measurements, ¹⁸F-CPFPX PET studies were calibrated by ex vivo experiments. Animals were killed by cervical dislocation on completion of the scan. Brains were removed immediately, frozen in 2-methylbutane at −50°C, and cut in coronal sections (thickness, 20 µm) with a cryostat microtome (CM 3050; Leica).

Image Processing and Statistical Analysis

Sections from autoradiographic experiments were placed on phosphor imaging plates (BAS-2R 2025; Raytest-Fuji) along with in-house–made and calibrated ¹⁸F brain paste standards for ¹⁸F studies or industrial ³H activity standards (Microscales; Amersham Biosciences) for ³H studies, respectively. Upon exposure, the imaging plates were scanned with a high-performance imaging plate reader (BAS 5000 BiolImage Analyzer; Raytest-Fuji) providing a spatial resolution of 50 µm.

The evaluation of digital receptor autoradiography was processed according to standard image analysis software (AIDA 2.31; Raytest). Competition and saturation curves were approximated numerically and calculated with standardized in-house–developed software and commercially available curve-fitting programs (Prism 3.0; GraphPad Software). Ex vivo autoradiographic data were corrected for injected dose, weight, decay, exposure time, and film efficacy before being analyzed with dedicated software (AIDA 2.31). Similarity of receptor densities as determined by PET and ex vivo autoradiography was analyzed with linear regression analysis using the same software.

RESULTS

CPFPX was labeled with ¹⁸F or ³H at the positions indicated in Figure 2. The 2 ligands are chemically identical.

In Vitro Distribution Studies

Anatomic distribution of ³H-CPFPX was evaluated with quantitative receptor autoradiography. We chose 12 ROIs to calculate absolute receptor binding. In vitro autoradiographic binding of ³H-CPFPX in rat demonstrated a typical pattern of cerebral A₁AR distribution with a low background and a high specific binding, particularly in gray matter regions. The highest receptor densities were found in the cerebellum, neocortex, and thalamus (Fig. 3). Nonspecific binding in rat brain amounted to a maximum of only 7% of total binding. A comparison of ³H-CPFPX and ¹⁸F-DPCPX binding established from adjacent serial sections revealed a highly significant similarity of the binding profiles of ³H-CPFPX and ¹⁸F-DPCPX (Fig. 4).

In Vitro Competition Studies

³H-CPFPX binding in rat brain was saturable, and Scatchard analysis revealed a K_d of 4.4 nmol/L (Fig. 5A). Competition studies were performed at ligand concentrations close to the K_d value. Competitor concentrations were chosen between 1 pmol/L and 10 µmol/L. The affinity to ³H-CPFPX binding sites was negligible (K_i >1 µmol/L) for various competitors from representative neurotransmitter systems, in particular amino acid systems (γ-aminobutyric acid, l-glutamate), monoaminergic transmitter systems (5-hydroxytryptamine, dopamine), and cholinergic systems (carbachol, nicotine). In contrast, the A₁AR antagonists CPFPX (K_i, 1.21 nmol/L), DPCPX (K_i, 6.29 nmol/L), and N-0840 (K_i, 11 nmol/L) competed for ³H-CPFPX binding sites in the nanomolar range. The unsel ective adenosine agonist (R−)-PIA (K_i, 39 nmol/L) and the antagonist caffeine (K_i, 216 nmol/L) were less effective in competing with ³H-CPFPX. ZM 241385, an A₂AAR-selective antagonist, displaced ³H-CPFPX in the high micromolar range (K_i, 15 µmol/L), underscoring the A₁AR selectivity of CPFPX (Fig. 5B).

In Vivo Animal PET and MRI Studies

High-resolution brain MRI scans obtained on all investigated animals served as an anatomic reference for a reliable

FIGURE 2. Structures of ¹⁸F-CPFPX (A) and ³H-CPFPX (B).

¹⁸F-CPFPX EVALUATION • Bauer et al.
identification of the brain. Inspection of the horizontal, coronal, and sagittal planes identified all major cranial and cerebral structures. The brain was clearly distinguishable from other cranial structures and was contoured accordingly on the MR datasets. The brain contours served as an overlay that was transferred to individually coregistered TierPET datasets.

After intravenous application, brain uptake of $^{18}$F-CPFPX was rapid (Fig. 6). Upon completion of the first frame (6 min after injection), the maximum of intracerebral uptake was already reached, followed by a gradual washout down to 67% of the maximum accumulation at the end of the scan (Fig. 6). Accumulation of radioactivity was high throughout the brain and extracranial soft tissues, particularly in the masseter muscles and the submandibular and harderior glands. Figure 7B is a representative example of the TierPET images. During the scanning procedure, $^{18}$F-CPFPX was metabolized into 2 polar metabolites to the extent of 54% ± 8% within 5 min.

To test the displaceability of $^{18}$F-CPFPX in vivo, 1 mg/kg DPCPX was injected 12 min after tracer administration. Figures 7B and 7C illustrate horizontal, coronal, and sagittal TierPET images of a representative animal after $^{18}$F-CPFPX (Fig. 7B) and after intravenous injection of DPCPX (Fig. 7C). DPCPX caused a rapid and significant displacement of cerebral $^{18}$F-CPFPX (62% ± 8% decrease of activity after 6
min; \( n = 3 \), indicating the specific and reversible binding of \(^{18}\text{F}-\text{CPFPX} \) (Fig. 6). In contrast, other cranial structures, particularly the masseter muscles and the submandibular glands, retain a considerable amount of activity, pointing to a nonspecific extracerebral ligand accumulation (Figs. 7B and 7C). In vivo PET experiments were completed by ex vivo dissection of the rat brains. Displacement of \(^{18}\text{F}-\text{CPFPX} \) by DPCPX amounted to 76\%/5\% in ex vivo measurements.

**DISCUSSION**

There is a substantial amount of evidence from in vitro studies that the neuromodulator adenosine and its receptors are involved in numerous processes of normal brain function as well as neuropathologic conditions, including epilepsy, Alzheimer’s disease, and cerebral ischemia. Given the importance of the adenosine system, in vivo imaging of the A\(_1\) AR, the most abundant cerebral adenosine receptor, has been a long-standing goal. This study pursues the evaluation process of \(^{18}\text{F}-\text{CPFPX} \), of which precursor synthesis, radiochemistry, basic ex vivo pharmacokinetics, and ex vivo distribution studies in mice have previously been reported (25).

CPFPX was labeled with either \(^3\text{H} \) or \(^{18}\text{F} \). Both ligands had identical chemical and binding properties. \(^3\text{H}-\text{CPFPX} \) was produced to facilitate and enhance the evaluation process, because \(^3\text{H}-\text{ligands} \) are comparatively stable tracers (half-life, 12.3 y) and, thus, easier to handle in incubation protocols. An additional advantage is that \(^3\text{H} \) gives a substantially higher resolution than \(^{18}\text{F} \) in autoradiographic studies. A high resolution is required to identify layer- or nucleus-specific distribution patterns, as shown in Figure 3, for example.

\(^3\text{H}-\text{CPFPX} \) demonstrated an A\(_1\) AR typical binding pattern in the rat brain. The labeled receptors had a highly heterogeneous distribution and were mainly concentrated in the cerebellar cortex, hippocampus, some thalamic nuclei, and cerebral cortex. In contrast, the hypothalamus and brain stem were sparse in binding. These results agree well with data from previous autoradiographic (5) and immunohistochemical (33,34) studies on the distribution of A\(_1\) ARs in the rat brain. They are also in excellent accordance with previous reports on the distribution of the A\(_1\) AR gold standard \(^3\text{H}-\text{DPCPX} \) (35,36). A direct comparison of both ligands demonstrated a highly significant correlation in cerebral ligand distribution. Saturation studies revealed that \(^3\text{H}-\text{CPFPX} \) bound with nanomolar affinity to a single and saturable binding site.
In numerous competition studies, it was clearly shown that \(^{3}H\)-CPFPX is not displaceable by ligands that have high affinities for other receptor systems having brain distributions like those of the A\(_1\)AR or by a selective A\(_2A\)AR antagonist. The latter is of special relevance for the high binding capacity of the caudate-putamen, the main brain region coexpressing A\(_1\)ARs and A\(_2A\)ARs. In contrast, \(^{3}H\)-CPFPX is displaceable in vitro and in vivo by DPCPX. All of these results provide substantial evidence that CPFPX is a highly specific and selective A\(_1\)AR ligand.

Thus far, high-resolution small animal PET has not been applied widely in the initial stages of ligand development, although its demand and potential benefit have repeatedly been emphasized (37,38). This study includes the application of in vivo imaging studies with a dedicated high-resolution small animal PET scanner to test the feasibility and the usefulness of this technique in the early process of ligand development.

Analysis of \(^{18}F\)-CPFPX PET time–activity curves revealed a rapid cerebral uptake of the ligand followed by a gradual washout over the 60-min scan time. The whole brain was defined as an ROI for further data processing. The kinetic data of \(^{18}F\)-CPFPX agreed with previous results of ex vivo mice experiments (25). To test the specificity of \(^{18}F\)-CPFPX binding, the A\(_1\)AR standard antagonist DPCPX was used as an unlabeled displacer, injected 12 min after scan onset. Within 6 min, the brain activity diminished to 62\% \pm 8\% of the baseline radioactivity. These data indicate that \(^{18}F\)-CPFPX is reversibly bound to cerebral A\(_1\)ARs and, thus, may be used to provide a direct measurement of drug-induced occupancy of A\(_1\)ARs in vivo. In contrast, other sites of ligand accumulation outside the rat cranium—for example, muscles of mastication and salivary glands—showed persistent activity after the administration of DPCPX, which is in accordance with the nonspecific accumulation of \(^{18}F\)-CPFPX and its metabolites. In summary, in vivo experiments support the view that \(^{18}F\)-CPFPX is a suitable PET ligand for the detection of A\(_1\)ARs.

**CONCLUSION**

This study demonstrates that \(^{18}F\)-CPFPX is a suitable radioligand for the in vivo imaging of A\(_1\)ARs with PET. It penetrates the blood–brain barrier rapidly, binds specifically and highly selectively to A\(_1\)ARs, and is displaceable in vivo. Additionally, this study demonstrates the effectiveness
of high-resolution small animal PET as a tool in the early evaluation process of radioligands.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the helpful comments of Dirk Bier, Institute of Nuclear Chemistry; and the excellent technical assistance of Sabine Wilms, Tobias Rustigé, and Ute Meisert (laboratory staff) as well as Maria-Liisa Grosse-Ruyken (MRI staff) of the Institute of Medicine; and Markus Lang, Bettina Palm, and Erika Wabballs of the Cyclotron and Radiosynthesis Staff of the Institute of Nuclear Chemistry. Both institutes are part of the Research Center Jülich. This work was supported by grants from the Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren (Strategiefonds), the American Heart Association (Cardiovascular Research, University of South Florida), and the Deutsche Forschungsgemeinschaft (SFB 757).

REFERENCES


18F-CPPX EVALUATION • Bauer et al. 1689
Evaluation of $^{18}$F-CPFPX, a Novel Adenosine $A_1$ Receptor Ligand: In Vitro Autoradiography and High-Resolution Small Animal PET


This article and updated information are available at:
http://jnm.snmjournals.org/content/44/10/1682

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml